
baransumer
@headnecksurgeon
ID: 60404756
http://www.utsouthwestern.edu/education/medical-school/departments/otolaryngology/index.html 26-07-2009 21:46:47
165 Tweet
124 Followers
332 Following



baransumer Thank you, Dr. Sumer, for your visit and for your contributions to advancing nanomedicine into the clinical practice. Our students and faculty COSAM and VCOM - Auburn Campus enjoyed your seminar. I highly recommend reading doi.org/10.1038/s41551…


Protocol Activation! NRG-HN014 "Randomized Phase III Trial of Neoadjuvant Immunotherapy With Response-Adapted Treatment Versus Standard-of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma” is open to patient entry. conta.cc/4ftFlhD Neil D. Gross, MD, FACS


Honored to be part of interdisciplinary team to promote UT Southwestern Medical Center. Magic place to ignite collaboration with Dr. Baran Sumer baransumer to advance cancer surgery and immunotherapy!



Thank you to #UTSW Professor Daniel Siegwart, Ph.D., who delivered an outstanding first presentation for this year’s President’s Lecture Series! It was a brilliant discussion of “Innovation in Nanotechnology: From Vaccines to Novel Genetic Disease Treatment.”









Congratulations to Zhijian "James" Chen, Ph.D., Professor of Molecular Biology UT Southwestern Medical Center, on being elected to the U.K.'s The Royal Society, the world's oldest scientific academy.


Check out Medical Vision Goggles, which help surgeons eliminate all cancer cells after tumor removal. Inventor Samuel Achilefu, Ph.D., Chair of UT Southwestern Biomedical Engineering, discusses the goggles and his goal of making them available to surgeons worldwide. bit.ly/3F6qAFg #UTSWScience

#BREAKING The FDA has approved pembrolizumab as the first new standard-of-care treatment for patients with resectable locally advanced #HeadandNeck cancer in 20+ years. Approval based on the pivotal KEYNOTE-689 trial led by Ravi Uppaluri, MDPhD of the Dana-Farber Brigham Cancer Center.


Exciting news in the head and neck cancer space. KEYNOTE-689 resulted in the first FDA approval for patients with HNSCC in 6 years. Congrats to Ravi Uppaluri, MDPhD, Doug Adkins, and the rest of the team worldwide. fda.gov/drugs/resource…